Amarillo, Texas, August 23, 2011 — Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that Colorado Serum Company (CSC) of Denver has taken an option to help commercialize ABI’s products for human and animal health. Primarily, CSC agreed to help evaluate ABI’s technology for animal health applications.
Using a method developed by ABI, CSC will manufacture bovine protein extract, an immune-system-boosting dietary ingredient that can be incorporated into products for use in animal health, a market CSC has served for nearly 90 years.
For human health, ABI plans to market dietary supplements containing CSC-manufactured bovine protein extract through health food stores under ABI’s brand name. A dietary supplement containing the bovine protein extract developed by ABI is already being marketed over the Internet under the name Virapress, with claims to 1) improve health and 2) enhance immunity.
“This agreement with CSC will enable Amarillo Biosciences to market bovine protein extract to the animal health market (through CSC), and allow us to pursue the human dietary supplement marketplace. We expect our branded dietary supplement to be on health-food store shelves starting in the fourth quarter of 2011,” said Joseph Cummins, President and CEO of ABI.
About Colorado Serum Company
Colorado Serum Company has been providing animal health products since 1923. Since its founding, the company has expanded its product lines to include a full range of large animal biologics, large animal veterinary instruments, veterinary diagnostics, specialty products and laboratory reagents. The company’s products are marketed and distributed by numerous animal health companies across the globe. For additional information, please visit the company’s website www.coloradoserum.com.
About Amarillo Biosciences
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 6% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive. The Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web at http://www.amarbio.com.
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company’s other product candidates and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. In particular, see “Item 1. Description of Business” and “Item 7A. Qualitative and Quantitative Disclosures about Market Risk” of the Company’s Form 10-K for the fiscal year ended December 31, 2010. --END--